Actelion, GSK Scrap Sleep Drug Almorexant
This article was originally published in The Pink Sheet Daily
The termination further hampers Actelion's efforts to diversify away from PAH drug Tracleer
You may also be interested in...
Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.
The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.
European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation
Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.